{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-067030","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.698264+00:00","generated_at":"2026-06-14T09:24:39.057891+00:00","sec_items":["2.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptimmune completes all-stock combination with TCR2; creates solid tumor cell therapy leader","bullets":["Merger closed June 1, 2023; Adaptimmune shareholders own ~75%, former TCR2 stockholders own ~25% of combined company.","BLA for afami-cel (synovial sarcoma) on track for mid-2023; 70% of responders alive at 2 years in SPEARHEAD-1 trial.","New directors appointed: Andrew Allen, Priti Hegde, Garry Menzel (ex-TCR2); Barbara Duncan and James Noble resigned.","Combined pipeline targets MAGE-A4, mesothelin, PRAME, CD70; company funded into early 2026.","Dr. Garry Menzel receives separation: $1.28M severance (18 months), $343,750 bonus, $171,875 transaction bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-067030","json":"https://secwatch.observer/filing/0001104659-23-067030.json","markdown":"https://secwatch.observer/filing/0001104659-23-067030.md","text":"https://secwatch.observer/filing/0001104659-23-067030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/tm2317177d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:24:39.057891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14b1044ca8","claim":"Andrew R. Allen was appointed as director at Adaptimmune Therapeutics PLC.","evidence_excerpt":"the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"3a630844c3","claim":"James Noble resigned as director at Adaptimmune Therapeutics PLC.","evidence_excerpt":"Barbara Duncan and James Noble resigned as directors of Adaptimmune.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"6f624b429a","claim":"Barbara Duncan resigned as director at Adaptimmune Therapeutics PLC.","evidence_excerpt":"Barbara Duncan and James Noble resigned as directors of Adaptimmune.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"91c4886509","claim":"Garry E. Menzel was appointed as director at Adaptimmune Therapeutics PLC.","evidence_excerpt":"the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"9620727323","claim":"Priti Hegde was appointed as director at Adaptimmune Therapeutics PLC.","evidence_excerpt":"the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"874f0df76cd79d05a66542d813438478b4fa3000","claim":"Adaptimmune Therapeutics PLC completed an acquisition involving TCR 2 Therapeutics Inc. for all-stock transaction (closed 2023-06-01).","evidence_excerpt":"On June 1, 2023, Adaptimmune Therapeutics plc, a public limited company incorporated in England and Wales (“ Adaptimmune ”), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to the Agreement and Plan of Merger entered into as of April 5, 2023 (as amended, the \" Merger Agreement \"), with TCR 2 Therapeutics Inc., a Delaware corporation (\" TCR 2 \"), Adaptimmune, and CM Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Adaptimmune (\" Merger Sub \").","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465923067030/0001104659-23-067030-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"TCR 2 Therapeutics Inc."},{"label":"Consideration","value":"all-stock transaction"},{"label":"Closing","value":"2023-06-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}